Advertisement

Prevalence of Ticarcillin/Clavulanic Acid-Resistant Enterobacteriacaeae in Nine Separate Medical Centers During the Years 1983, 1989, and 1991

  • Arthur L. Barry
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 349)

Abstract

The combination of ticarcillin with clavulanic acid has proven to be an effective antimicrobial agent. For in vitro susceptibility testing doubling dilutions of ticarcillin are combined with a fixed concentration of 2 µg clavulanic acid per ml.5,6 Resistance to ticarcillin/clavulanic acid (T/C) has been relatively uncommon among the Enterobacteriaceae.2,5,6,9 In 1988, Sanders et al. described strains of Escherichia coli and Klebsiella pneumoniae that were T/C resistant because they produced excess amounts of β-lactamase enzymes which could not be completely neutralized by the low concentration of clavulanic acid (2 µg/ml) that is normally tested in vitro.11 Whether strains with elevated T/C MICs should be considered clinically resistant is a matter of presumption. The inability of the disk diffusion test to detect such hyper-producers of β-lactamase enzymes has been studied, but the clinical relevance of those discrepant results has yet to be evaluated.3,7,11

Keywords

Medical Center Clavulanic Acid Klebsiella Oxytoca Disk Diffusion Test Interpretive Criterion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A.L. Barry, Antistaphylococcal activity of amoxicillin and ticarcillin when combined with clavulanic acid, evaluation of oxacillin-resistant and oxacillin-susceptible isolates. Diagn. Microbiol. Infect. Dis. 13:357–361 (1990).PubMedCrossRefGoogle Scholar
  2. 2.
    A.L. Barry, L.W. Ayers, T.L. Gavan, E.H. Gerlach, and R.N. Jones, In vitro activity of ticarcillin plus clavulanic acid against bacteria isolated in three centers, Eur. J. Clin. Microbiol., 3:203–206 (1984).PubMedCrossRefGoogle Scholar
  3. 3.
    A.L. Barry, P.C. Fuchs, E.H. Gerlach, D.J. Hardy, J.C. McLaughlin, and MA Pfaller, Ticarcillin and ticarcillin/clavulanic acid susceptibility tests: error rates for disk tests with consecutively isolated Enterbacteriaceae, Antimicrob. Agents Chemother., 36:137–143 (1992).PubMedCrossRefGoogle Scholar
  4. 4.
    A.L. Barry, C. Thornsberry, R.N. Jones, and T.L. Gavan, In vitro activity of mezlocillin and azlocillin compared to that of four other penicillins and two aminoglycosides. Cleveland Clinic Quarterly 47:311–319 (1980).PubMedGoogle Scholar
  5. 5.
    P.C. Fuchs, A.L. Barry, and R.N. Jones, In vitro activity and disk susceptibility of Timentin: current status, Amer. J. Med. 79 Suppl 5B:25–32 (1985).PubMedCrossRefGoogle Scholar
  6. 6.
    P.C. Fuchs, A.L. Barry, C. Thornsberry, and R.N. Jones, In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates, Antimicro. Agents Chemother., 25:392–394 (1984).CrossRefGoogle Scholar
  7. 7.
    P.C. Fuchs, R.N. Jones, and A.L. Barry, Reassessment of susceptibility test interpretive criteria for ticarcillin and ticarcillin-clavulanic acid, J. Clin. Microbiol., 27:2475–2481 (1989).PubMedGoogle Scholar
  8. 8.
    R.N. Jones, A.L. Barry, R.V. Gardiner, and R.R. Packer, The prevalence of staphylococcal resistance to penicillinase-resistant penicillin: a retrospective and prospective national surveillance trial of isolates from 40 medical centers, Diagn. Microbiol. Infect. Dis., 12:385–394 (1989).PubMedCrossRefGoogle Scholar
  9. 9.
    R.N. Jones, M.A. Pfaller, P.C. Fuchs, K. Aldridge, S.D. Allen, and E.H. Gerlach, Piperacillin/Tazobactam (YTR830) combination, comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains, Diagn. Microbiol. Infect Dis., 12:489–494 (1989).PubMedCrossRefGoogle Scholar
  10. 10.
    National Committee for Clinical Laboratory Standards, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Approved Standard M7-A2 (2nd ed.) NCCLS, Villanova, PA (1990).Google Scholar
  11. 11.
    C.C. Sanders, J.P. Jaconis, G.P. Bodey, and G. Samonis, Resistance to ticarcillinpotassium clavulanate among clinical isolates of the family Enterobacteriacae: role of PSE-1 β-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests, Antimicrob. Agents Chemother., 32:1365–1369 (1988).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Arthur L. Barry
    • 1
  1. 1.The Clinical Microbiology InstituteTualatinUSA

Personalised recommendations